Amgen launches Phase 3 trial of monthly obesity drug MariTide and raises full‑year EPS outlook
Amgen announced that its experimental obesity therapy MariTide entered a Phase 3 trial in Q3, comparing it with Novo Nordisk's semaglutide. The drug aims to reduce injections from the current 52 per year to as few as four or twelve per year. In the same quarter the company reported revenue of $10.4 billion, up 8% year‑over‑year, and non‑GAAP EPS of $6.45, up 14%, prompting an increase in its full‑year adjusted EPS guidance to $22.90‑$23.70 per share. CEO Robert Bradway said the results reflect a strong quarter and the outlook was lifted accordingly.
Why it matters
The raised EPS guidance signals higher expected earnings for the year, which may support Amgen's share price. Investors will watch the 2027 Phase 3 readouts, as success could add a differentiated, convenient obesity product to Amgen's portfolio and expand its exposure to the $114 billion market projected for 2030.
Key facts
- 1Amgen began a Phase 3 trial of MariTide versus semaglutide in Q3. finance.biggo.com
- 2MariTide is designed for once‑monthly or once‑quarterly dosing, potentially reducing injections from 52 per year to 12 or four per year. finance.biggo.com
- 3Q3 revenue was $10.4 billion, up 8% year over year. finance.biggo.com
- 4Non‑GAAP earnings per share for Q3 were $6.45, up 14% from the prior year. finance.biggo.com
- 5Full‑year adjusted EPS guidance was raised to a range of $22.90‑$23.70 per share. finance.biggo.com
- 6CEO Robert Bradway said Amgen "delivered another strong quarter" during the earnings call. finance.biggo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.